Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid

FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid) for the Treatment of PBC

April 7, 2016 5:00 PM EDT

PDUFA Date is May 29, 2016

Intercept to host investor conference call today at 5:30 p.m. ET

NEW YORK, April 07, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration (FDA)s Gastrointestinal Drugs Advisory Committee voted 17 to 0 to recommend accelerated approval of Ocaliva (obeticholic acid) for the treatment of patients with... More